Neoadjuvant Treatment for Resectable and Locally Advanced Pancreatic Cancer

  • Rebecca P. Petersen
  • Johanna C. Bendell
  • Brian G. Czito
  • Douglas S. Tyler
Part of the M. D. Anderson Solid Tumor Oncology Series book series (MDA)

Pancreatic carcinoma is the fourth leading cause of cancer death in the United States, resulting in over 30,000 deaths per year. The overall prognosis is poor, with a 5-year survival rate of 4% for all stages (1). Although it is debatable if this disease can be cured through surgical resection, only a minority of patients (15–20%) present with potentially resectable disease that warrants an attempt at surgery. Even with advances in operative techniques and perioperative care, prognosis remains suboptimal for patients undergoing complete resection, as the 5-year survival is <20% (2). Efforts to improve on outcomes with radical surgery have focused on combined strategies of adjuvant and neoadjuvant chemotherapy alone or in conjunction with radiation therapy.

In an attempt to improve upon the efficacy of adjuvant chemoradiation therapy, interest in neoadjuvant treatment approaches has increased. Approximately one third of patients who undergo resection do not receive planned postoperative therapy due to complications of surgery or delayed recovery ( 3, 4 ). In contrast, all patients who are resected following neoadjuvant therapy have received the potential benefit of multimodality therapy and there appears to be a significantly lower rate of major complications post-pancreaticoduodenectomy, such as pancreatic leaks (5 ). Other theoretical advantages include improved delivery of chemotherapy and radiosensitizing oxygen to tissues whose blood supply has not been disrupted by surgery, as well as the avoidance of irradiation to fixed loops of bowel postoperatively.


Pancreatic Cancer Clin Oncol Advanced Pancreatic Cancer Chemoradiation Therapy Resectable Pancreatic Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jemal A, Siegel R, Ward E, Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106.CrossRefPubMedGoogle Scholar
  2. 2.
    Sohn TA, Yeo CJ, Cameron JL, 2000, Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567–579.CrossRefPubMedGoogle Scholar
  3. 3.
    Klinkenbijl JH, Jeekel J, Sahmoud T, 1999, Adjuvant radiotherapy and 5 fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776–782.CrossRefPubMedGoogle Scholar
  4. 4.
    Yeo CJ, Abrams RA, Grochow LB, 1997, Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225:621–633.CrossRefPubMedGoogle Scholar
  5. 5.
    Cheng T, Sheth K, White RR, 2006, Effect of Neoadjuvant Chemoradiation on Operative Mortality and Morbidity for Pancreaticoduodenectomy. Ann Surg Oncol 13: 66–74.CrossRefPubMedGoogle Scholar
  6. 6. Willett CG, Warshaw AL. Intraoperative electron beam irradiation in pancreatic cancer. Frontiers in Bioscience, 1998.Google Scholar
  7. 7.
    White R, Hurwitz H, Lee C, 2001, Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 8:758–765.CrossRefPubMedGoogle Scholar
  8. 8.
    Kim HJ, Czischke K, Brennan MF, 2002, Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? J Gastrointest Surg. 6(5):763–769.CrossRefPubMedGoogle Scholar
  9. 9.
    White RR, Kattan MW, Haney JC, 2006, Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram. Ann Surg Oncol 13:1485–1492.CrossRefPubMedGoogle Scholar
  10. 10.
    Evans DB, Abbruzzese JL, Willett CG. 2001, Cancer of the pancreas. In: DeVita VT Jr Hellman S, Rosenberg SA (eds.) Cancer: principles and practice of oncology, 6 th ed. Lippincott, Philadelphia, 1138th ed..Google Scholar
  11. 11.
    Horwhat JD, Paulson EK, McGrath K, 2006, A randomized comparison of EUS-guided FNA versus CT or US-guided FNA for the evaluation of pancreatic mass lesions. Gastroint Endosc 63:966–975.CrossRefGoogle Scholar
  12. 12.
    Micames C, Jowell P, White R, 2003, Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs percutaneous FNA. Gastrointest Endosc 58:690–695.CrossRefPubMedGoogle Scholar
  13. 13.
    Moertel CG, Childs DS Jr, Reitemeier RJ, Colby My Jr, Holbrook MA, 1969, Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2(7626): 865–867.CrossRefPubMedGoogle Scholar
  14. 14.
    Moertel CG, Frytak S, Hahn RG, 1981, Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48:1705–1710.CrossRefPubMedGoogle Scholar
  15. 15.
    Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group. Cancer 1985, 56:2563–2568.CrossRefPubMedGoogle Scholar
  16. 16.
    Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988, 80:751–755.CrossRefGoogle Scholar
  17. 17.
    Klaassen DJ, MacIntyre JM, Catton GE, 1985, Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol 3:373–378.PubMedGoogle Scholar
  18. 18.
    Jessup JM, Steele G Jr Mayer RJ, 1993, Neoadjuvant therapy for unresectable pancreatic ade-nocarcinoma. Arch Surg 128:559.PubMedGoogle Scholar
  19. 19.
    Kamthan AG, Morris JC, Dalton J, 1997, Combined modality therapy for stage II and stage III pancreatic carcinoma. J Clin Oncol 15:2920–2927.PubMedGoogle Scholar
  20. 20.
    Wanebo HJ, Glicksman AS, Vezeridis MP, 2000, Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg 135: 81–87.CrossRefPubMedGoogle Scholar
  21. 21.
    Snady H, Bruckner H, Cooperman A, 2000, Survival advantage of combined chemoradio-therapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 89:314–327.Google Scholar
  22. 22.
    Ammori JB, Colletti LM, Zalupski MM, 2003, Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 7(6):766–772.CrossRefPubMedGoogle Scholar
  23. 23.
    Aristu J, Canon R, Pardo F, 2003, Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. Am J Clin Oncol 26: 30–36.CrossRefPubMedGoogle Scholar
  24. 24.
    White RR, Tyler DS. 2004, Neoadjuvant therapy for pancreatic cancer: the Duke experience. Surg Oncol Clin North Am 13: 675–684.CrossRefGoogle Scholar
  25. 25.
    Joensuu TK, Kiviluoto T, Kärkkäinen P, 2004, Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Rad Oncol 60:444–452.Google Scholar
  26. 26.
    Pipas MJ, Barth RK, Zaki B, 2005, Docetaxel/gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 12:995–1004.CrossRefPubMedGoogle Scholar
  27. 27.
    Spitz FR, Abbruzzese JL, Lee JE, 1997, Preoperative and postoperative chemoradiation strate-gies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15(3):928–937.PubMedGoogle Scholar
  28. 28.
    Yeung RS, Weese JL, Hoffman JP, 1993, Neoadjuvant chemoradiation in pancreatic and duo-denal carcinoma. A Phase II Study. Cancer 72:2124–2133.CrossRefPubMedGoogle Scholar
  29. 29.
    Hoffman JP, Lipsitz S, Pisansky T, 1998, Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 16:317–312.PubMedGoogle Scholar
  30. 30.
    Moutardier V, Magnin V, Turrini O, 2004, Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 60: 437.PubMedGoogle Scholar
  31. 31.
    Mornex F, Girard N, Delpero JR, 2005, Radiochemotherapy in the management of pancreatic cancer—part I: neoadjuvant treatment. Semin Radiat Oncol 15:226–234.CrossRefPubMedGoogle Scholar
  32. 32.
    Staley CA, Lee JE, Cleary KA, 1996, Preoperative chemoradiation, pancreaticoduodenec-tomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 171:118.CrossRefPubMedGoogle Scholar
  33. 33.
    Pisters PW, Abbruzzese JL, Janjan NA, 1998, Rapid-fractionation preoperative chemoradia-tion, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 16:3843.PubMedGoogle Scholar
  34. 34.
    Pisters PW, Wolff RA, Janjan NA, 2002, Preoperative paclitaxel and concurrent rapid-frac-tionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 20:2537.CrossRefPubMedGoogle Scholar
  35. 35.
    Wolff RA, Evans DB, Crane CH, 2002, Initial results of preoperative gemcitabine-based chemora-diation for resectable pancreatic adenocarcinoma (abstract). Proc Am Soc Clin Oncol 21: 130a.Google Scholar
  36. 36.
    Meszoely IM, Wang H, Hoffman JP. 2004, Preoperative chemoradiation therapy for adenocar-cinoma of the pancreas: The Fox Chase Cancer Center experience, 1986-2003. Surg Oncol Clin North Am 13(4):685–696.CrossRefGoogle Scholar
  37. 37.
    Talamonti MS, Small W, Mulcahy MF, 2006, A multi-institutional Phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 13:150–158.CrossRefPubMedGoogle Scholar
  38. 38.
    White R, Xie B, Gotfried M, 2005, Prognostic significance of histologic response to preopera-tive chemoradiation of periampullary malignancies. Ann Surg Oncol 12:214–221.CrossRefPubMedGoogle Scholar
  39. 39.
    Kindler HL, Friberg G, Singh DA, 2005, Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 31: 8033–8040.CrossRefGoogle Scholar
  40. 40.
    Kindler HL, Friberg G, Singh DA, 2005, Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 1 (23): 8033–8040.CrossRefGoogle Scholar
  41. 41.
    Kortmansky S, O’Reilly EM, Minsky BD, 2005, A phase I trial of erlotinib, gemcitabine and radiation for patients with locally advanced, unresectable pancreatic cancer. J Clin Oncol 23:4107.CrossRefGoogle Scholar
  42. 42.
    Xiong HQ, Rosenberg A, LoBuglio A. 2004, Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 22:2610–2616.CrossRefPubMedGoogle Scholar
  43. 43. Pipas JM, Zaki B, Suriawinata AA, et al. Cetuximab, intensity-modulated radiotherapy (IMRT), and twice-weekly gemcitabine for pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 2006 (abstract 14056).Google Scholar
  44. 44. Krempien RC, Munter MW, Timke C, et al. Phase II study evaluating trimodal therapy with cetuximab intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer (ISRCTN56652283). Proc Am Soc Clin Oncol, 2006 (abstract 4100).Google Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Rebecca P. Petersen
    • 1
  • Johanna C. Bendell
    • 2
  • Brian G. Czito
    • 3
  • Douglas S. Tyler
    • 1
  1. 1.Department of SurgeryDuke University Medical CenterDurhamUSA
  2. 2.Division of Medical Oncology, Department of MedicineDuke University Medical CenterDurhamUSA
  3. 3.Department of Radiation OncologyDuke University Medical CenterDurhamUSA

Personalised recommendations